Baillie Gifford & CO Sutro Biopharma, Inc. Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
A detailed history of Baillie Gifford & CO transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 48,791 shares of STRO stock, worth $86,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,791
Previous 1,519,341
96.79%
Holding current value
$86,360
Previous $5.26 Million
98.31%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding STRO
# of Institutions
128Shares Held
59.9MCall Options Held
203KPut Options Held
33.6K-
Suvretta Capital Management, LLC New York, NY7.46MShares$13.2 Million0.57% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$7.45 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.64MShares$6.45 Million0.42% of portfolio
-
Vestal Point Capital, LP New York, NY2.57MShares$4.55 Million0.28% of portfolio
About SUTRO BIOPHARMA, INC.
- Ticker STRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,161,500
- Market Cap $92.3M
- Description
- Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...